Jane Wasman

Currently holds a position at Rigel Pharmaceuticals Inc

2.4

2.4

Position	Company	Period
Independent Director	Rigel Pharmaceuticals Inc	March 22, 2019 -

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2025-06-02	2025-05-30	Sellas Life Sciences Group Inc (SLS)	B Purchase	85,009 +38.1% 431.04 US$91,696	85,009 +38.1%	431.04	US$91,696
2019-12-04	2019-12-02	Acorda Therapeutics Inc (ACOR)	PlS Planned sale	8,437 +12.8% 479.39 US$1,360,191	8,437 +12.8%	479.39	US$1,360,191
2018-12-06	2018-12-03	Acorda Therapeutics Inc (ACOR)	PlS Planned sale	45,336 +38.3% 239.93 US$4,592,320	45,336 +38.3%	239.93	US$4,592,320
2017-12-05	2017-12-01	Acorda Therapeutics Inc (ACOR)	PlS Planned sale	4,564 -4.3% 20.52 US$93,662	4,564 -4.3%	20.52	US$93,662
2016-10-05	2016-10-03	Acorda Therapeutics Inc (ACOR)	PlS Planned sale	3,750 -3.4% 20.78 US$77,927	3,750 -3.4%	20.78	US$77,927